Literature DB >> 26621287

Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark.

Marie Borggren1, Sanne Skov Jensen1, Leo Heyndrickx2, Angelica A Palm3, Jan Gerstoft4, Gitte Kronborg5, Bo Langhoff Hønge6,7,8, Sanne Jespersen6, Zacarias José da Silva9, Ingrid Karlsson1, Anders Fomsgaard1,10.   

Abstract

The development of therapeutic and prophylactic HIV vaccines for African countries is urgently needed, but the question of what immunogens to use needs to be answered. One approach is to include HIV envelope immunogens derived from HIV-positive individuals from a geographically concentrated epidemic with more limited viral genetic diversity for a region-based vaccine. To address if there is a basis for a regional selected antibody vaccine, we have screened two regionally separate cohorts from Guinea-Bissau and Denmark for neutralizing antibody activity and antibody-dependent cellular cytotoxicity (ADCC) against local and nonlocal circulating HIV-1 strains. The neutralizing activity did not demonstrate higher potential against local circulating strains according to geography and subtype determination, but the plasma from Danish individuals demonstrated significantly higher inhibitory activity than that from Guinea-Bissau individuals against both local and nonlocal virus strains. Interestingly, an opposite pattern was observed with ADCC activity, where Guinea-Bissau individual plasma demonstrated higher activity than Danish plasma and was specifically against the local circulating subtype. Thus, on basis of samples from these two cohorts, no local-specific neutralizing activity was detected, but a local ADCC response was identified in the Guinea-Bissau samples, suggesting potential use of regional immunogens for an ADCC-inducing vaccine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26621287      PMCID: PMC4845637          DOI: 10.1089/AID.2015.0118

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  63 in total

1.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 3.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

Review 4.  Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Authors:  Penny L Moore; Carolyn Williamson; Lynn Morris
Journal:  Trends Microbiol       Date:  2015-01-05       Impact factor: 17.079

5.  Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Authors:  Adjoa Smalls-Mantey; Nicole Doria-Rose; Rachel Klein; Andy Patamawenu; Stephen A Migueles; Sung-Youl Ko; Claire W Hallahan; Hing Wong; Bai Liu; Lijing You; Johannes Scheid; John C Kappes; Christina Ochsenbauer; Gary J Nabel; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

6.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

7.  Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants.

Authors:  J K Carr; M O Salminen; J Albert; E Sanders-Buell; D Gotte; D L Birx; F E McCutchan
Journal:  Virology       Date:  1998-07-20       Impact factor: 3.616

8.  HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: origin, demography and migrations.

Authors:  Joakim Esbjörnsson; Mattias Mild; Fredrik Månsson; Hans Norrgren; Patrik Medstrand
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

9.  Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study.

Authors:  Inés Oliveira; Andreas Andersen; Alcino Furtado; Candida Medina; David da Silva; Zacarias J da Silva; Peter Aaby; Alex Lund Laursen; Christian Wejse; Jesper Eugen-Olsen
Journal:  BMJ Open       Date:  2012-11-14       Impact factor: 2.692

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  3 in total

1.  Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals.

Authors:  Ingrid Karlsson; Jeanette Linnea Tingstedt; Gülşen Özkaya Şahin; Mikkel Hansen; Zsofia Szojka; Marcus Buggert; Antonio Biague; Zacharias Da Silva; Fredrik Månsson; Joakim Esbjörnsson; Hans Norrgren; Patrik Medstrand; Anders Fomsgaard; Marianne Jansson
Journal:  J Infect Dis       Date:  2019-05-05       Impact factor: 5.226

Review 2.  HIV-2 as a model to identify a functional HIV cure.

Authors:  Joakim Esbjörnsson; Marianne Jansson; Sanne Jespersen; Fredrik Månsson; Bo L Hønge; Jacob Lindman; Candida Medina; Zacarias J da Silva; Hans Norrgren; Patrik Medstrand; Sarah L Rowland-Jones; Christian Wejse
Journal:  AIDS Res Ther       Date:  2019-09-05       Impact factor: 2.250

3.  Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.

Authors:  Dieter Mielke; Sherry Stanfield-Oakley; Bhavesh Borate; Allan C deCamp; Guido Ferrari; Leigh H Fisher; Katelyn Faircloth; Marina Tuyishime; Kelli Greene; Hongmei Gao; Carolyn Williamson; Lynn Morris; Christina Ochsenbauer; Georgia Tomaras; Barton F Haynes; David Montefiori; Justin Pollara
Journal:  J Virol       Date:  2021-11-03       Impact factor: 6.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.